AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01433549 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
Study NCT01433549 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A
Description: Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
Study NCT01447420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 180 mcg sc weekly, 48 weeks
Study NCT01447420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1'000 or 1'200 mg orally daily, 48 weeks
Study NCT00268476 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy to the prostate
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04024839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Isolated Stretch
Description: In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.
Study NCT04024839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Isometric Relaxation
Description: In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
Study NCT01857843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zotalolimus Eluting Stent
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1.
Study NCT01857843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1.
Study NCT01857843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg & Simvastatin 40mg
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)
Study NCT01857843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin 20mg
Description: Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)
Study NCT03123432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: immunomodulating nutrients enriched diet
Study NCT03123432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard diet
Study NCT03111537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes
Description: Smoke their usual brand of cigarettes and follow their normal patterns of use.
Study NCT02176408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
Study NCT02176408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
Study NCT02176408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
Study NCT02176408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Intervention
Description: Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
Study NCT02105974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: 100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
Study NCT02105974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: 25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Oestradiol
Study NCT04672317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy combined with chemotherapy
Description: Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy
Study NCT01118897 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)~Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.~Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy.
Study NCT05969613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional block
Description: regional block with 0.25% Bupivacaine at a dose of 2ml/kg with adrenaline
Study NCT05969613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Infiltration of surgical site with 0.25% Bupivacaine at 0.5ml/kg dose
Study NCT05969613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Infiltration of caudal epidural space with 0.25% Bupivacaine at 1ml/kg dose
Study NCT02377427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
Study NCT02697825 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Schiotz tonometer for Intraocular Pressure
Description: Both Values will be corelated
Study NCT02967744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: NSAIDs are among the most common pain treatments for patients with osteoarthritis.
Study NCT03387332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
Study NCT03903276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: Tens
Study NCT03111537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarette
Description: Use of E-cigarette: multiple flavors offered.
Study NCT03111537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Gum or Lozenge
Description: Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
Study NCT02371512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip system (Abbott Vascular, Menlo Park, USA)
Description: Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
Study NCT02272595 — intervention group
Intervention type: OTHER
Intervention: Treatment Based on Genetic Mutation
Description: Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
Study NCT02272595 — intervention group
Intervention type: OTHER
Intervention: Treatment Based on No Genetic Mutation
Description: Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
Study NCT02622308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowOx™
Description: FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
Study NCT01405248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide
Description: 20 mg/time per os three times a day. 180days
Study NCT01405248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg/time per os three times a day. 180days
Study NCT02371512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve surgery
Description: Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
Study NCT04157439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Hot fermentation was applied for 10 mints Sustain pressure on trigger point was applied with thumb for 3secs hold and 2 sec release (till pain is reduced).~Self-stretches of cervical muscles (10 reps× 1set) For home plan cervical muscles stretching and postural care was guided
Study NCT04157439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Hot fermentation was applied for 10 mints. Integrated Neuromuscular Inhibition Technique \[sustain pressure, Post Isometric Relaxation (PIR) and SCS\]. Sustain pressure was applied on trigger points using thumb for 3 sec hold and 2 mints release (till pain is reduced).~Post isometric stretch (MET) was given with 4 repetitions (6-10sec hold). Strain counter strain was given in which upper trapezius shortened position was maintained by slight flexion, same side bending, opposite rotation and shoulder abduction for 90 sec and repeats this procedure till the pain is reduced to 3 out of 10.~Self-stretches for cervical muscles were done at the end of session to maintain the gained ranges (10 reps×1 set) For home plan cervical muscles stretching and postural care was guided
Study NCT03143439 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fathers Advancing Communities Together (FACT) program
Description: The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
Study NCT03576976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
Study NCT03576976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
Study NCT02155062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain rye
Study NCT02155062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain wheat
Study NCT02155062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined cereal
Study NCT02155062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined cereal
Study NCT02055716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforadex
Study NCT02055716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alpha-cyclodextrin
Study NCT04448483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paretic upper limb functional electric stimulation through RehaStim
Description: The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release.
Study NCT04448483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive transcranial current stimulation through DC-Stimulator
Description: Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.
Study NCT01804621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Newsletter
Description: Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
Study NCT03673332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immune-checkpoint inhibitors therapies
Description: All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
Study NCT04010487 — intervention group
Intervention type: GENETIC
Intervention: whole exome sequencing and RNA-sequencing
Description: The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
Study NCT02076698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AN-DBS
Description: Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
Study NCT02076698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment
Description: usual treatment of epilepsy Vagus nerve stimulation: maintained
Study NCT02898337 — intervention group
Intervention type: DEVICE
Intervention: AliveCor handheld mobile ECG
Description: Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center.
Study NCT00289471 — intervention group
Intervention type: OTHER
Intervention: No intervention delivered.
Description: No intervention delivered.
Study NCT03542474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Endurance Exercise
Description: Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
Study NCT04449718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 200,000 IU on admission
Study NCT00479609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal testosterone therapy
Description: testosterone 1% hydroalcohol gel
Study NCT00479609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel
Study NCT03602482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Description: Participants will stand and complete cognitive tests.
Study NCT03602482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supine
Description: Participants will complete cognitive tests while supine.
Study NCT01372137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-H94
Description: Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
Study NCT01372137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose 5%
Description: Placebo
Study NCT01007084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40 mg
Study NCT01007084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol ER
Description: 120 mg twice per day
Study NCT01007084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pills
Description: sugar pill
Study NCT01850875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye-Movement-Desensitization-Reprocessing
Study NCT04433377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Description: A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector
Study NCT04433377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subacromial injection
Description: A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
Study NCT02417597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.